Treatment - Page 51 of 471 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Improved outcomes with linagliptin in patients with persistent prediabetes after metformin and lifestyle modifications.

Improved outcomes with linagliptin in patients with persistent prediabetes after metformin and lifestyle modifications.

Posted by on Jun 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study evaluated the addition of linagliptin (Trajenta) to metformin (Glucophage) and lifestyle changes in patients with persistent prediabetes. The authors concluded that adding linagliptin after 12 months of metformin treatment and lifestyle changes improved glucose levels and pancreatic β-cell function in these...

Read More

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Comparing metformin extended-release to metformin immediate-release for adults with type 2 diabetes.

Posted by on Jun 6, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and tolerance of metformin (Glucophage) extended-release (MXR) and conventional metformin immediate-release (MIR) in adults with type 2 diabetes (T2D). The authors concluded that MIR had better glucose control while MXR but reduced gastrointestinal (GI) side effects. Some background...

Read More

Comparing enucleation and resection for BPH in medium-sized prostates

Comparing enucleation and resection for BPH in medium-sized prostates

Posted by on Jun 6, 2021 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study compared the effectiveness and safety of holmium laser enucleation of the prostate (HoLEP), bipolar transurethral enucleation of the prostate (bTUEP), and transurethral resection of the prostate (TURP) for patients with benign prostatic hyperplasia (BPH) in medium-sized prostates. The authors concluded that all...

Read More

Sacral neuromodulation improves clinical outcomes in patients that failed first-line Botulinum toxin treatment for overactive bladder

Sacral neuromodulation improves clinical outcomes in patients that failed first-line Botulinum toxin treatment for overactive bladder

Posted by on Jun 6, 2021 in Overactive bladder | 0 comments

In a nutshell This study investigated the effectiveness of sacral neuromodulation (SNM) in patients with overactive bladder (OAB) that failed previous Botulinum toxin A (Botox; BTA) treatment. Researchers suggested that SNM is a good method in patients who failed first-line treatment. Some background OAB causes a sudden urge to urinate that is...

Read More

Does adding chemotherapy after surgery for liver metastasis improve the long-term outcome of patients with colorectal cancer?

Does adding chemotherapy after surgery for liver metastasis improve the long-term outcome of patients with colorectal cancer?

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The study investigated the impact of adding chemotherapy after surgery to remove liver metastasis on the outcomes of patients with colorectal cancer (CRC). The study reported a significantly longer survival in patients undergoing further chemotherapy. Some background Up to 50% of patients with CRC develop...

Read More

Reviewing treatment options for bone disease in patients with multiple myeloma

Reviewing treatment options for bone disease in patients with multiple myeloma

Posted by on Jun 6, 2021 in Multiple Myeloma | 0 comments

In a nutshell This article reviewed different treatment options for multiple myeloma (MM)-related bone disease.  Some background MM is a type of cancer of the bone marrow that can lead to abnormal immune cells. Up to 80% of newly diagnosed patients develop bone disease. These patients have a high risk of bone problems, such as fractures and...

Read More

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

FOLFIRINOX before pre-surgery treatment can improve the outcomes of patients with rectal cancer

Posted by on Jun 6, 2021 in Colorectal cancer | 0 comments

In a nutshell The aim of this study was to investigate FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, and fluorouracil) before pre-surgery chemoradiotherapy (CRT) for patients with rectal cancer (RC). The study found that FOLFIRINOX given before CRT and surgery improved the outcomes of these patients. Some background RC can be treated with...

Read More

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Comparing carfilzomib to bortezomid combined with cyclophosphamide and dexamethasone in patients with previously treated multiple myeloma

Posted by on Jun 5, 2021 in Multiple Myeloma | 0 comments

In a nutshell This trial was carried out to compare bortezomib (Velcade; V) and carfilzomib (Kyprolis; K) in combination with Cd (cyclophosphamide and dexamethasone) as second line treatment in patients with relapsed multiple myeloma (MM). The authors found the KCd is as effective as VCd and K can also be used as a maintenance treatment in these...

Read More

Long-term outcomes of focal cryotherapy in low- to intermediate-risk prostate cancer.

Long-term outcomes of focal cryotherapy in low- to intermediate-risk prostate cancer.

Posted by on Jun 5, 2021 in Prostate cancer | 0 comments

In a nutshell This study looked at the use of focal cryotherapy (FC) for the treatment of low- to intermediate-risk prostate cancer (PC). The authors found that the use of FC was safe and increased time to further therapy with similar survival compared to active surveillance (AS).  Some background PC is one of the most common forms of...

Read More

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients.  Some background Lung cancer...

Read More

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This review was carried out to analyze the effectiveness and safety of EGFR tyrosine kinase inhibitors (TKIs) plus chemotherapy (CT) versus EGFR-TKIs alone as a treatment for advanced non-small-cell lung cancer (NSCLC) that is EGFR-positive. The authors found that EGFR-TKIs and CT treatment improved survival for these patients while...

Read More